Companies › Chengdu Zenitar Biomedical Technology
4 active drug programs in 11 registered trials: 6 Phase 2, 3 Phase 1, 2 Phase 3; Oncology, Other, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Purinostat Mesylate for Injection Class Ia and IIb HDAC selective inhibitor | HDAC (class I/II) | Phase 3 | Recurrent and Refractory Diffuse Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma,DLBCL; Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL); Relapsed or Refractory Multiple Myeloma (RRMM) … | Dec 2026 |
| Flonoltinib Maleate JAK1/JAK2 inhibitor | JAK1, JAK2 | Phase 3 | MF; MF,PMF,PPV-MF,PET-MF; Polycythemia Vera (PV) | May 2027 |
| ZL-82 | – | Phase 2 | Atopic Dermatitis | Dec 2027 |
| ZL-65 tablet | – | Phase 1 | Healthy Participants Study | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06484829 | Purinostat Mesylate for Injection | Phase 1 | Relapsed or Refractory Multiple Myeloma (RRMM) | Oncology | Feb 2026 |
| NCT06431243 | Purinostat Mesylate for Injection | Phase 1 | Advanced Solid Tumor | Oncology | May 2026 |
| NCT05563844 | Purinostat Mesylate for Injection | Phase 2 | Diffuse Large B Cell Lymphoma,DLBCL | Oncology | Dec 2026 |
| NCT06485219 | Purinostat Mesylate for Injection | Phase 2 | Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Oncology | Dec 2026 |
| NCT06457425 | Flonoltinib Maleate | Phase 2 | MF,PMF,PPV-MF,PET-MF | Other | May 2027 |
| NCT07232290 | Flonoltinib Maleate | Phase 2 | Polycythemia Vera (PV) | Oncology | Jul 2027 |
| NCT07757152 | ZL-65 tablet | Phase 1 | Healthy Participants Study | Other | Jul 2027 |
| NCT07317700 | Flonoltinib Maleate | Phase 3 | MF | Oncology | Dec 2027 |
| NCT07443306 | Flonoltinib Maleate | Phase 2 | MF | Oncology | Dec 2027 |
| NCT07193589 | ZL-82 | Phase 2 | Atopic Dermatitis | Immunology | Dec 2027 |
| NCT07011056 | Purinostat Mesylate for Injection | Phase 3 | Recurrent and Refractory Diffuse Large B-cell Lymphoma | Oncology | Jun 2029 |
Incyte AbbVie Pfizer Chia Tai Tianqing Pharmaceutical Group Sun Pharmaceutical Industries Alfasigma Takeda Eli Lilly LEO Pharma GSK
Dizal Pharmaceuticals Shanghai Kechow Pharma J-Pharma Beijing InnoCare Pharma Tech InventisBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.